

# CITATION REPORT

List of articles citing

**Demyelination, inflammation, and neurodegeneration  
in multiple sclerosis deep gray matter**

**DOI: 10.1097/nen.0b013e3181a19a5a**  
**Journal of Neuropathology and Experimental  
Neurology, 2009, 68, 489-502.**

**Source:** <https://exaly.com/paper-pdf/47354349/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
203	Cannabinoids, multiple sclerosis and neuroprotection. <b>2009</b> , 2, 645-60		11
202	Neuroinflammation responses and neurodegeneration in multiple sclerosis. <b>2009</b> , 165, 1023-8		13
201	Current concepts in the neuropathology and pathogenesis of multiple sclerosis. <b>2010</b> , 37 Suppl 2, S5-15		16
200	Multiple sclerosis: autoimmune disease or autoimmune reaction?. <b>2010</b> , 37 Suppl 2, S16-23		26
199	Combination therapy in multiple sclerosis. <b>2010</b> , 9, 299-308		91
198	The inhibitory neurotransmitter glycine modulates macrophage activity by activation of neutral amino acid transporters. <b>2010</b> , 88, 2420-30		23
197	A novel decalcification method for adult rodent bone for histological analysis of peripheral-central nervous system connections. <b>2010</b> , 187, 59-66		17
196	Attention Network Test reveals alerting network dysfunction in multiple sclerosis. <b>2010</b> , 16, 93-9		57
195	Thalamic damage and long-term progression of disability in multiple sclerosis. <b>2010</b> , 257, 463-9		107
194	Identification et quantification d'une neurodégénérescence précoce au cours de la sclérose en plaques avec la tomographie à émission de positons au [11C]-Flumazenil. <b>2010</b> , 166, S33-S34		
193	3T deep gray matter T2 hypointensity correlates with disability over time in stable relapsing-remitting multiple sclerosis: a 3-year pilot study. <b>2010</b> , 297, 76-81		21
192	Imaging evaluation of demyelinating processes of the central nervous system. <b>2010</b> , 86, 218-29		11
191	The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. <b>2010</b> , 224, 92-102		56
190	Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. <b>2011</b> ,		7
189	Inflammation, demyelination, and degeneration - recent insights from MS pathology. <b>2011</b> , 1812, 275-82		160
188	Microarray analyses of laser-captured hippocampus reveal distinct gray and white matter signatures associated with incipient Alzheimer's disease. <b>2011</b> , 42, 118-26		134
187	Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis. <b>2011</b> , 2011, 767083		16

186	Matrix metalloproteinases and their tissue inhibitors in cuprizone-induced demyelination and remyelination of brain white and gray matter. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2011</b> , 70, 758-69	3.1	34
185	Triiodothyronine administration ameliorates the demyelination/remyelination ratio in a non-human primate model of multiple sclerosis by correcting tissue hypothyroidism. <b>2011</b> , 23, 778-90		26
184	Cholinergic imbalance in the multiple sclerosis hippocampus. <b>2011</b> , 122, 313-22		55
183	Cortical injury in multiple sclerosis; the role of the immune system. <b>2011</b> , 11, 152		12
182	Gray matter imaging in multiple sclerosis: what have we learned?. <b>2011</b> , 11, 153		64
181	The pathology of multiple sclerosis and related disorders. <b>2011</b> , 17, 225-231		1
180	Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. <b>2011</b> , 4, 139-68		58
179	The puzzle of multiple sclerosis: gray matter finds its place. <b>2011</b> , 11, 1565-8		5
178	Cortical diffusion-tensor imaging abnormalities in multiple sclerosis: a 3-year longitudinal study. <b>2011</b> , 261, 891-8		70
177	Thalamic damage predicts the evolution of primary-progressive multiple sclerosis at 5 years. <b>2011</b> , 32, 1016-20		50
176	Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis. <b>2011</b> , 17, 702-7		19
175	APOE $\epsilon$ is associated with exacerbation of cognitive decline in patients with multiple sclerosis. <b>2011</b> , 24, 128-33		15
174	Multimodal quantitative magnetic resonance imaging of thalamic development and aging across the human lifespan: implications to neurodegeneration in multiple sclerosis. <b>2011</b> , 31, 16826-32		49
173	Hypothalamus syndrome in opticospinal multiple sclerosis. <b>2011</b> , 32, E153-5		3
172	Examination of the relationship between average plaque volume and clinical and demographic characteristics in multiple sclerosis patients using a stereological method. <b>2011</b> , 121, 366-72		
171	Gray matter pathology in MS: a 3-year longitudinal study in a pediatric population. <b>2012</b> , 33, 1507-11		19
170	Pathology of multiple sclerosis. <b>2012</b> , 11, 506-17		45
169	Neuropathologic correlates of magnetic resonance imaging in multiple sclerosis. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2012</b> , 71, 762-78	3.1	18

168	Blood-brain barrier alterations in the cerebral cortex in experimental autoimmune encephalomyelitis. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2012</b> , 71, 840-54	3.1	49
167	Fluoxetine for multiple sclerosis. <b>2012</b> ,		
166	Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. <b>2012</b> , 135, 2925-37		238
165	Neurite outgrowth is differentially impacted by distinct immune cell subsets. <b>2012</b> , 49, 68-76		17
164	Immunology meets neuroscience--opportunities for immune intervention in neurodegenerative diseases. <b>2012</b> , 26, 1-10		27
163	Classifying minimally disabled multiple sclerosis patients from resting state functional connectivity. <b>2012</b> , 62, 2021-33		75
162	Physiopathology of symptoms and signs in multiple sclerosis. <b>2012</b> , 70, 733-40		16
161	Lipocalin 2 is present in the EAE brain and is modulated by natalizumab. <b>2012</b> , 6, 33		56
160	Pathogenic implications of iron accumulation in multiple sclerosis. <b>2012</b> , 120, 7-25		102
159	Recent insights into the pathology of multiple sclerosis and neuromyelitis optica. <b>2013</b> , 115 Suppl 1, S38-41		12
158	Promoting remyelination in multiple sclerosis--recent advances. <b>2013</b> , 73, 2017-29		55
157	The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. <b>2013</b> , 80, 210-9		222
156	DTI detects water diffusion abnormalities in the thalamus that correlate with an extremity pain episode in a patient with multiple sclerosis. <b>2013</b> , 2, 258-62		26
155	Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. <b>2013</b> , CD008933 <sub>92</sub>		
154	Cognitive and neuropsychiatric disease manifestations in MS. <b>2013</b> , 2, 4-12		38
153	Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. <b>2013</b> , 19, 1153-60		17
152	Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations. <b>2013</b> , 2013, 627870		18
151	Sodium accumulation is associated with disability and a progressive course in multiple sclerosis. <b>2013</b> , 136, 2305-17		85

150	Grey matter damage in multiple sclerosis: a pathology perspective. <b>2013</b> , 7, 66-75	63
149	Increased concentrations of glutamate and glutamine in normal-appearing white matter of patients with multiple sclerosis and normal MR imaging brain scans. <b>2013</b> , 8, e61817	53
148	Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression. <b>2013</b> , 8, e70019	40
147	Normal appearing and diffusely abnormal white matter in patients with multiple sclerosis assessed with quantitative MR. <b>2014</b> , 9, e95161	45
146	Altered inter-subregion connectivity of the default mode network in relapsing remitting multiple sclerosis: a functional and structural connectivity study. <b>2014</b> , 9, e101198	40
145	Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. <b>2014</b> , 85, 1386-95	201
144	Label-fusion-segmentation and deformation-based shape analysis of deep gray matter in multiple sclerosis: the impact of thalamic subnuclei on disability. <b>2014</b> , 35, 4193-203	31
143	Reductions in neuronal peroxisomes in multiple sclerosis grey matter. <b>2014</b> , 20, 651-9	28
142	Impaired Object Handling during Bimanual Task Performance in Multiple Sclerosis. <b>2014</b> , 2014, 450420	5
141	Multiple sclerosis: altered thalamic resting-state functional connectivity and its effect on cognitive function. <b>2014</b> , 271, 814-21	88
140	Multiple sclerosis: lessons from molecular neuropathology. <b>2014</b> , 262 Pt A, 2-7	87
139	Remyelinating strategies in multiple sclerosis. <b>2014</b> , 14, 1315-34	19
138	Mechanisms and pharmacology of neuropathic pain in multiple sclerosis. <b>2014</b> , 20, 75-97	11
137	Gray matter involvement in multiple sclerosis and neuromyelitis optica. <b>2014</b> , 5, 69-76	1
136	Pathology of multiple sclerosis and related inflammatory demyelinating diseases. <b>2014</b> , 122, 15-58	179
135	Increased thalamic intrinsic oscillation amplitude in relapsing-remitting multiple sclerosis associated with the slowed cognitive processing. <b>2014</b> , 38, 605-10	13
134	Understanding disease processes in multiple sclerosis through magnetic resonance imaging studies in animal models. <b>2014</b> , 4, 743-56	32
133	Immune Response in the Human Central Nervous System in Multiple Sclerosis and Stroke. <b>2015</b> , 1-19	2

132	Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple Sclerosis. <b>2015</b> , 2015, 725370	75
131	Significance of gray matter brain lesions in multiple sclerosis and neuromyelitis optica. <b>2015</b> , 35, 481-6	9
130	Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis. <b>2015</b> , 138, 2571-83	56
129	Neuronal and axonal loss in normal-appearing gray matter and subpial lesions in multiple sclerosis. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2015</b> , 74, 453-8	3.1 44
128	Exploring the origins of grey matter damage in multiple sclerosis. <b>2015</b> , 16, 147-58	250
127	Thalamic lesions in multiple sclerosis by 7T MRI: Clinical implications and relationship to cortical pathology. <b>2015</b> , 21, 1139-50	41
126	Pathological mechanisms in progressive multiple sclerosis. <b>2015</b> , 14, 183-93	660
125	What drives MRI-measured cortical atrophy in multiple sclerosis?. <b>2015</b> , 21, 1280-90	66
124	Thalamus pathology in multiple sclerosis: from biology to clinical application. <b>2015</b> , 72, 1127-47	42
123	Gray matter damage in multiple sclerosis: Impact on clinical symptoms. <b>2015</b> , 303, 446-61	48
122	Multimodal Quantitative MR Imaging of the Thalamus in Multiple Sclerosis and Neuromyelitis Optica. <b>2015</b> , 277, 784-92	30
121	Memory impairment in multiple sclerosis: Relevance of hippocampal activation and hippocampal connectivity. <b>2015</b> , 21, 1705-12	47
120	The thalamus as a putative biomarker in neurodegenerative disorders. <b>2015</b> , 49, 502-18	14
119	Morphological Abnormalities of Thalamic Subnuclei in Migraine: A Multicenter MRI Study at 3 Tesla. <b>2015</b> , 35, 13800-6	46
118	Thalamic atrophy predicts cognitive impairment in relapsing remitting multiple sclerosis. Effect on instrumental activities of daily living and employment status. <b>2015</b> , 358, 236-42	32
117	Cognitive impairment in multiple sclerosis: clinical, radiologic and pathologic insights. <b>2015</b> , 25, 79-98	90
116	Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST). <b>2015</b> , 7, 43-52	18
115	Regional patterns of grey matter atrophy and magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups: a voxel-based analysis study. <b>2015</b> , 21, 423-32	13

114	The Role of the Choroid Plexus in the Pathogenesis of Multiple Sclerosis. <b>2016</b> , 103-127	1
113	Functional cortical changes in relapsing-remitting multiple sclerosis at amplitude configuration: a resting-state fMRI study. <b>2016</b> , 12, 3031-3039	3
112	Intrinsic Functional Plasticity of the Thalamocortical System in Minimally Disabled Patients with Relapsing-Remitting Multiple Sclerosis. <b>2016</b> , 10, 2	11
111	A New Approach for Deep Gray Matter Analysis Using Partial-Volume Estimation. <b>2016</b> , 11, e0148631	6
110	Early silent microstructural degeneration and atrophy of the thalamocortical network in multiple sclerosis. <b>2016</b> , 37, 1866-79	37
109	Relationship of grey and white matter abnormalities with distance from the surface of the brain in multiple sclerosis. <b>2016</b> , 87, 1212-1217	36
108	Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. <b>2016</b> , 16, 777-93	94
107	Central fatigue in multiple sclerosis: a review of the literature. <b>2016</b> , 39, 386-99	37
106	Correlation of Apparent Diffusion Coefficient to cognitive impairment in Relapsing remittent multiple sclerosis (plaque, peri-plaque and Normal appearing white matter). <b>2016</b> , 47, 1009-1018	2
105	Neuroinflammatory component of gray matter pathology in multiple sclerosis. <b>2016</b> , 80, 776-790	114
104	Thalamus Degeneration and Inflammation in Two Distinct Multiple Sclerosis Animal Models. <b>2016</b> , 60, 102-14	18
103	The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis. <b>2016</b> , 5, 215-229	18
102	Progressive multiple sclerosis: from pathogenic mechanisms to treatment. <b>2017</b> , 140, 527-546	210
101	Application of laser radiation and magnetostimulation in therapy of patients with multiple sclerosis. <b>2016</b> , 38, 183-90	5
100	Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis. <b>2016</b> , 73, 795-802	43
99	Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients. <b>2016</b> , 22, 1327-36	68
98	Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis. <b>2016</b> , 22, 668-76	27
97	Lesion Expansion in Experimental Demyelination Animal Models and Multiple Sclerosis Lesions. <b>2016</b> , 53, 4905-17	13

96	Combined structural and functional patterns discriminating upper limb motor disability in multiple sclerosis using multivariate approaches. <b>2017</b> , 11, 754-768	15
95	Cortical Gray Matter MR Imaging in Multiple Sclerosis. <b>2017</b> , 27, 301-312	21
94	Insights from Ultrahigh Field Imaging in Multiple Sclerosis. <b>2017</b> , 27, 357-366	2
93	Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis. <b>2017</b> , 127, 971-980	10
92	New rapid, accurate T quantification detects pathology in normal-appearing brain regions of relapsing-remitting MS patients. <b>2017</b> , 14, 363-370	11
91	Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis. <b>2017</b> , 23, 1469-1478	17
90	Progressive iron accumulation across multiple sclerosis phenotypes revealed by sparse classification of deep gray matter. <b>2017</b> , 46, 1464-1473	15
89	Reply. <b>2017</b> , 81, 324-325	4
88	Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex. <b>2017</b> , 82, 259-270	58
87	Neuropsychology of Multiple Sclerosis: Looking Back and Moving Forward. <b>2017</b> , 23, 832-842	52
86	Inflammatory demyelination alters subcortical visual circuits. <b>2017</b> , 14, 162	21
85	Iron-Insensitive Quantitative Assessment of Subcortical Gray Matter Demyelination in Multiple Sclerosis Using the Macromolecular Proton Fraction. <b>2018</b> , 39, 618-625	17
84	Reproducibility of Deep Gray Matter Atrophy Rate Measurement in a Large Multicenter Dataset. <b>2018</b> , 39, 46-53	11
83	Emerging drugs for primary progressive multiple sclerosis. <b>2018</b> , 23, 97-110	8
82	Multiple Sclerosis Pathology. <b>2018</b> , 8,	225
81	Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS. <b>2018</b> , 39, 289-295	19
80	Brain atrophy in multiple sclerosis: How deep must we go?. <b>2018</b> , 83, 208-209	3
79	Multiple Immune-Inflammatory and Oxidative and Nitrosative Stress Pathways Explain the Frequent Presence of Depression in Multiple Sclerosis. <b>2018</b> , 55, 6282-6306	35



78	Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain. <b>2018</b> , 18, 1007-1016	20
77	Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality. <b>2018</b> , 167, 438-452	43
76	Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: Insights from 7 T imaging. <b>2018</b> , 24, 1433-1444	25
75	Multiple sclerosis. <b>2018</b> , 4, 43	372
74	The Bayesian risk estimate at onset (BREMSO) correlates with cognitive and physical disability in patients with early multiple sclerosis. <b>2018</b> , 26, 96-102	1
73	Meningeal inflammation and cortical demyelination in acute multiple sclerosis. <b>2018</b> , 84, 829-842	57
72	Myelin water imaging to detect demyelination and remyelination and its validation in pathology. <b>2018</b> , 28, 750-764	27
71	Monitoring Progressive Multiple Sclerosis with Novel Imaging Techniques. <b>2018</b> , 7, 265-285	11
70	Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis. <b>2018</b> , 289, 487-496	48
69	Iron related changes in MS lesions and their validity to characterize MS lesion types and dynamics with Ultra-high field magnetic resonance imaging. <b>2018</b> , 28, 743-749	20
68	Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS. <b>2018</b> , 28, 399-405	8
67	Postmortem magnetic resonance imaging. <b>2018</b> , 150, 335-354	3
66	Brain fibrinogen deposition plays a key role in MS pathophysiology - Yes. <b>2019</b> , 25, 1434-1435	4
65	Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study. <b>2019</b> , 6, e587	15
64	Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis. <b>2019</b> , 90, 642-651	89
63	Five year iron changes in relapsing-remitting multiple sclerosis deep gray matter compared to healthy controls. <b>2019</b> , 33, 107-115	8
62	Enhanced GABAergic Immunoreactivity in Hippocampal Neurons and Astroglia of Multiple Sclerosis Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2019</b> , 78, 480-491	3.1 11
61	Myelinoclastic diffuse sclerosis (Schilder's disease) is immunologically distinct from multiple sclerosis: results from retrospective analysis of 92 lumbar punctures. <b>2019</b> , 16, 51	11

60	Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis. <b>2019</b> , 7,	41
59	Contribution of normal aging to brain atrophy in MS. <b>2019</b> , 6,	27
58	Relapsing-Remitting Multiple Sclerosis Is Associated With Regional Brain Activity Deficits in Motor- and Cognitive-Related Brain Areas. <b>2019</b> , 10, 1136	6
57	Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis. <b>2018</b> , 9, 3116	187
56	Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study. <b>2019</b> , 40, 99-106	23
55	What Causes Deep Gray Matter Atrophy in Multiple Sclerosis?. <b>2019</b> , 40, 107-108	5
54	Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis. <b>2019</b> , 27, 305-311	4
53	Association between pathological and MRI findings in multiple sclerosis. <b>2019</b> , 18, 198-210	86
52	Increased mean R2* in the deep gray matter of multiple sclerosis patients: Have we been measuring atrophy?. <b>2019</b> , 50, 201-208	16
51	Preserved canonicity of the BOLD hemodynamic response reflects healthy cognition: Insights into the healthy brain through the window of Multiple Sclerosis. <b>2019</b> , 190, 46-55	3
50	Convergent effects of a functional C3 variant on brain atrophy, demyelination, and cognitive impairment in multiple sclerosis. <b>2019</b> , 25, 532-540	13
49	New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis. <b>2020</b> , 267, 192-202	5
48	7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. <b>2020</b> , 26, 177-187	28
47	Cortical projection neurons as a therapeutic target in multiple sclerosis. <b>2020</b> , 24, 1211-1224	0
46	Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy. <b>2020</b> , 30, 251-266	14
45	Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging. <b>2020</b> , 7,	14
44	The Impact of Intracortical Lesions on Volumes of Subcortical Structures in Multiple Sclerosis. <b>2020</b> , 41, 804-808	3
43	Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis. <b>2020</b> , 267, 1536-1546	15

42	Intrinsic and Extrinsic Mechanisms of Thalamic Pathology in Multiple Sclerosis. <b>2020</b> , 88, 81-92	18
41	MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. <b>2020</b> , 20, 821-834	6
40	Characterization of thalamic lesions and their correlates in multiple sclerosis by ultra-high-field MRI. <b>2021</b> , 27, 674-683	5
39	Iron deposition and atrophy in cerebral grey matter and their possible association with serum iron in relapsing-remitting multiple sclerosis. <b>2021</b> , 69, 238-242	0
38	In vivo gradients of thalamic damage in paediatric multiple sclerosis: a window into pathology. <b>2021</b> , 144, 186-197	9
37	Deep gray matter changes in relapsing-remitting multiple sclerosis detected by multi-parametric, high-resolution magnetic resonance imaging (MRI). <b>2021</b> , 31, 706-715	1
36	Pathology of Multiple Sclerosis. <b>2021</b> , 105-116	
35	Explainable 3D-CNN for Multiple Sclerosis Patients Stratification. <b>2021</b> , 103-114	
34	Platelets in Multiple Sclerosis: Early and Central Mediators of Inflammation and Neurodegeneration and Attractive Targets for Molecular Imaging and Site-Directed Therapy. <b>2021</b> , 12, 620963	4
33	Contribution of Gray Matter Atrophy and White Matter Damage to Cognitive Impairment in Mildly Disabled Relapsing-Remitting Multiple Sclerosis Patients. <b>2021</b> , 11,	0
32	Deep grey matter injury in multiple sclerosis: a NAIMS consensus statement. <b>2021</b> , 144, 1974-1984	4
31	Acute and chronic synaptic pathology in multiple sclerosis gray matter. <b>2021</b> , 13524585211022174	2
30	Neurocognitive performance in relapsing-remitting multiple sclerosis patients is associated with metabolic abnormalities of the thalamus but not the hippocampus- GABA-edited 1H MRS study. <b>2021</b> , 1-8	
29	Neuroanatomical changes seen in MRI in patients with cerebral metastasized breast cancer after radiotherapy. <b>2021</b> , 3008916211031301	
28	In silico Analysis of Transcriptomic Profiling and Affected Biological pathways in Multiple Sclerosis.	0
27	Enteric Nervous System in Neonatal Necrotizing Enterocolitis. <b>2021</b> ,	1
26	Structural disconnectivity from paramagnetic rim lesions is related to disability in multiple sclerosis. <b>2021</b> , 11, e2353	3
25	On the potential for mapping apparent neural soma density via a clinically viable diffusion MRI protocol. <b>2021</b> , 239, 118303	4

24	Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron MRI. <b>2021</b> , 42, 1463-1474	9
23	Multifaceted involvement of microglia in gray matter pathology in multiple sclerosis. <b>2021</b> , 39, 993-1007	4
22	Structural disconnectivity from quantitative susceptibility mapping rim+ lesions is related to disability in people with multiple sclerosis.	2
21	Detection of Cortical and Deep Gray Matter Lesions in Multiple Sclerosis Using DIR and FLAIR at 3T. <b>2021</b> , 31, 408-414	2
20	Recent advances in understanding multiple sclerosis. <b>2019</b> , 8,	21
19	Tissue transglutaminase in marmoset experimental multiple sclerosis: discrepancy between white and grey matter. <b>2014</b> , 9, e100574	11
18	Linking immune-mediated damage to neurodegeneration in multiple sclerosis: could network-based MRI help?. <b>2021</b> , 3, fcab237	1
17	Brain Morphometry in Multiple Sclerosis. <b>2018</b> , 279-300	
16	[What do we know about the pathology of gray matter in multiple sclerosis]. <b>2018</b> , 118, 18-22	
15	Multiple Sclerosis. <b>2020</b> , 1-35	
14	Inflammatory Conditions of the Hypothalamus. <b>2021</b> , 437-478	
13	The association between neurodegeneration and local complement activation in the thalamus to progressive multiple sclerosis outcome.. <b>2022</b> , e13054	1
12	Innate Immune Cell-Related Pathology in the Thalamus Signals a Risk for Disability Progression in Multiple Sclerosis.. <b>2022</b> , 9,	1
11	Cognitive Decline in Older People with Multiple Sclerosis: A Narrative Review of the Literature. <b>2022</b> , 7, 61	
10	Ependymal-infiltration and gradient of thalamic damage in progressive multiple sclerosis.	0
9	Quantitative MRI in Multiple Sclerosis: From Theory to Application.	0
8	Neurodegeneration in multiple sclerosis.	0
7	Longitudinal changes of deep gray matter shape in multiple sclerosis. <b>2022</b> , 35, 103137	0

- 6 Periventricular remyelination failure in multiple sclerosis: a substrate for neurodegeneration. ○
- 5 Lesion-Specific Metabolic Alterations in Relapsing-Remitting Multiple Sclerosis Via 7 T Magnetic Resonance Spectroscopic Imaging. Publish Ahead of Print, ○
- 4 Chronic experimental autoimmune encephalomyelitis is an excellent model to study neuroaxonal degeneration in multiple sclerosis. 15, ○
- 3 RNA-Binding Proteins as Epigenetic Regulators of Brain Functions and Their Involvement in Neurodegeneration. **2022**, 23, 14622 ○
- 2 Is There Reduced Hemodynamic Brain Activation in Multiple Sclerosis Even with Undisturbed Cognition?. **2023**, 24, 112 ○
- 1 Women in the field of multiple sclerosis: How they contributed to paradigm shifts. 16, ○